Parabilis Medicines, Inc. Common Stock (PBLS)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Market Cap
- $4.5B
About Parabilis Medicines, Inc. Common Stock
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.
SentiSense also tracks daily options readings for Parabilis Medicines, Inc. Common Stock: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Parabilis Medicines, Inc. Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.